Race Oncology 2022 AGM Presentation by CEO Phil Lynch and CSO Dr Daniel Tillett.
Race Oncology Limited (ASX:RAC) is an Australian pharmaceutical company focused on the development of its key drug, Zantrene, which is currently being studied for pre-clinical and clinical efficacy in several cancer indications. Zantrene is a highly targeted precision oncology agent…
To discuss or comment on this announcement please visit our Investor Hub.
To discuss or comment on this announcement please visit our Investor Hub.
Race Oncology CEO Phillip Lynch and CSO Dr Daniel Tillett present Race’s June 2022 Quarterly Investor Briefing followed by a Q&A session.